Biotech

All Articles

Amgen files initial period 3 win for $400M chronic eczema medication

.Amgen has shared (PDF) the 1st period 3 records on its $400 million eczema medicine, linking the an...

Biogen, UCB document stage 3 lupus gain after neglecting earlier test

.Biogen as well as UCB's bank on advancing in to period 3 astride a broken research seeks to have ac...

Aptadir wishes new RNA preventions may reverse complicated cancers cells

.Italian biotech Aptadir Rehabs has introduced with the commitment that its pipeline of preclinical ...

Wave surfs DMD results to regulators' doors, sending stock up

.Surge Lifestyle Sciences has actually fulfilled its objective in a Duchenne muscular dystrophy (DMD...

Sanofi picks new CSO coming from in-stealth biotech

.After a couple of years in biotech, Mike Quigley, Ph.D., is going back to the pharma layer, taking ...

Achilles splashes cell therapy course, braces for unemployments after missing 'commercial stability' goals

.Achilles Therapies has torn up its approach. The British biotech is actually knocking off on its cl...

Aligos declares period 2 MASH succeed, slashing liver excess fat as much as 46%

.Aligos Therapies is actually proclaiming a midstage win in metabolic-dysfunction affiliated steatoh...

Basilea credit ratings $268M BARDA financing for antifungals, anti-biotics

.Basilea Pharmaceutica's job building brand new antifungals has acquired a notable increase from the...

Capricor markets Europe liberties to late-stage DMD treatment for $35M

.Having actually scooped up the USA liberties to Capricor Rehabs' late-stage Duchenne muscular dystr...

FDA junks adcomm for Applied's uncommon condition medicine

.After pushing the decision date for Applied Rehabs' metabolic ailment medication govorestat, the FD...